![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, February 16, 2021 11:26:27 PM
Dr. DeGrado will be the "KEYNOTE SPEAKER" for the "COMPUTATIONAL PROTEIN ENGINEERING AND DESIGN" at Cambridge Healthtech Institute's 23rd Annual Conference on Tuesday May 11th.
He will speak at 1:50 pm and his presentation will be:
Computational Design of Binding Proteins (...the process used to develop Brilacidin)
Display of Biologics
"Designing Antibody Drugs of the Future"
The field of biologics has relied on the engine of display technologies to produce a breadth of constructs that include bispecific antibodies, antibody-drug conjugates, immunotherapy constructs, and antibodies targeting SARS, MERS and emerging coronaviruses as well as membrane proteins with ever greater potency and target specificity. This year’s program will feature blockbuster papers that cover a range of exciting developments- don’t miss the premier event of the year.
This talk will focus on new approaches to de novo computational design of proteins...might we hear more about his baby...BRILACIDIN???
ABOUT DR. DEGRADO:
William (Bill) DeGrado’s work focuses on the design of small molecule drugs, peptides, proteins to address biological and mechanistic questions. Since 2011, Bill has been a professor in the Department of Pharmaceutical Chemistry at the University of California San Francisco, where he is also a member of the Cardiovascular Research Institute and an adjunct member of the Institute for Neurodegenerative Diseases. Prior to UCSF, he was he was a member of DuPont Central Research and DuPont Merck Pharmaceutical Company from 1981 to 1996 and the Raiziss
1. Professor in the Department of Biochemistry and Biophysics at the University of Pennsylvania (1996 – 2011).
He has served as a visiting professor or adjunct faculty at:
2.Harvard (Department of Chemistry:
3.Johns Hopkins (Biophysics),
4.University of Pennsylvania (Biochemistry & Biophysics) and UCSF (Pharmaceutical Chemistry).
Some of Dr. DeGrado's research interests include: de novo design of proteins and peptides; peptide mimetics; protein mis-folding diseases, structure/function of membrane proteins, including integrins and viral ion channels; small molecule drug design; bioinorganic chemistry.
https://www.pegsummit.com/Phage-Display#WilliamDeGrado
Question for this board......
Who thinks they know more about the potential of Brilacidin than Dr. DeGrado????
Anyone who claims all of their comments are pro rated should not be trusted!!
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM